Allelic loss of a common microsatellite marker MYCL1:: A useful prognostic factor of poor outcomes in colorectal cancer

被引:12
|
作者
Kambara, T
Sharp, GB
Nagasaka, T
Takeda, M
Sasamoto, H
Nakagawa, H
Isozaki, H
MacPhee, DG
Jass, JR
Tanaka, N
Matsubara, N
机构
[1] Okayama Univ, Grad Sch Med & Dent, Dept Gastroenterol Surg & Surg Oncol, Okayama 7008558, Japan
[2] Radiat Effects Res Fdn, Dept Epidemiol, Hiroshima, Japan
[3] McGill Univ, Dept Pathol, Montreal, PQ, Canada
关键词
D O I
10.1158/1078-0432.CCR-0779-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Allelic loss involving chromosome arms 5q, 8p, 17p, and 18q is commonly detected in colorectal cancer (CRC). The short arm of chromosome 1 is also frequently affected in a whole range of cancer types, including CRC. Our aim in the present study was to determine whether allelic losses on 1p were likely to be of much value in predicting the prognosis of CRC cases. Experimental Design: Genomic DNA was prepared from tumor and corresponding normal tissue specimens from 90 patients who had undergone curative resection for CRC. Loss of heterozygosity (LOH) on chromosome arms 1p, 2p, 5q, 7q, 8p, 17p, 17q, and 18q was examined using 14 microsatellite markers, and possible correlations between LOH and clinicopathological factors (including tumor recurrence and patient survival) were investigated. LOH at the MYCL1 microsatellite marker at 1p34 was detected in 12 of 74 (16.2%) patients who were informative for this marker. Results: After controlling for tumor stage and gender and excluding findings for patients with remote metastasis, we found that patients who were positive for LOH at MYCL1 were 31 times more likely to experience recurrence than those who were negative for LOH at this locus (95% confidence intervals, 2.27-infinity; P = 0.04). There were indications of a similar tendency for LOH at the 14-3-3-sigma-TG microsatellite marker at 1p35, but we could find no evidence of a significant association between LOH at this site and tumor recurrence or patient survival. We were also unable to detect significant association between LOH at the various sites on 2p, 5q, 7q, 8p, 17p, 17q, and 18q and either tumor recurrence or patient survival. Conclusions: CRC patients whose tumors exhibited LOH at MYCL1 at chromosome 1p34 were likely to have a poor prognosis, suggesting that this marker may have clinical relevance.
引用
收藏
页码:1758 / 1763
页数:6
相关论文
共 40 条
  • [31] Specific 8-oxo-dGTPase activity of MTH1 (NUDT1) protein as a quantitative marker and prognostic factor in human colorectal cancer
    Bialkowski, Karol
    Szpila, Anna
    FREE RADICAL BIOLOGY AND MEDICINE, 2021, 176 : 257 - 264
  • [32] Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer
    Nishio, Shin
    Ushijima, Kimio
    Yamaguchi, Tomohiko
    Sasajima, Yuko
    Tsuda, Hitoshi
    Kasamatsu, Takahiro
    Kage, Masayoshi
    Ono, Mayumi
    Kuwano, Michihiko
    Kamura, Toshiharu
    GYNECOLOGIC ONCOLOGY, 2014, 132 (03) : 703 - 708
  • [33] Dipeptidase 1 (DPEP1) is a marker for the transition from low-grade to high-grade intraepithelial neoplasia and an adverse prognostic factor in colorectal cancer
    P A Eisenach
    E Soeth
    C Röder
    G Klöppel
    J Tepel
    H Kalthoff
    B Sipos
    British Journal of Cancer, 2013, 109 : 694 - 703
  • [34] Dipeptidase 1 (DPEP1) is a marker for the transition from low-grade to high-grade intraepithelial neoplasia and an adverse prognostic factor in colorectal cancer
    Eisenach, P. A.
    Soeth, E.
    Roeder, C.
    Kloeppel, G.
    Tepel, J.
    Kalthoff, H.
    Sipos, B.
    BRITISH JOURNAL OF CANCER, 2013, 109 (03) : 694 - 703
  • [35] A Truncated NRIP1 Mutant Amplifies Microsatellite Instability of Colorectal Cancer by Regulating MSH2/MSH6 Expression, and Is a Prognostic Marker of Stage III Tumors
    Palassin, Pascale
    Lapierre, Marion
    Pyrdziak, Samuel
    Wagner, Antoine
    Stehle, Regine
    Corsini, Carole
    Duffour, Jacqueline
    Bonnet, Sandrine
    Boulahtouf, Abdelhay
    Rodriguez, Carmen
    Ho-Pun-Cheung, Alexandre
    Lopez-Crapez, Evelyne
    Boissiere-Michot, Florence
    Bibeau, Frederic
    Thezenas, Simon
    Elarouci, Nabila
    Selves, Janick
    Hoffmann, Jean-Sebastien
    Roepman, Paul
    Mazard, Thibault
    Buhard, Olivier
    Duval, Alex
    Jalaguier, Stephan
    Cavailles, Vincent
    Castet-Nicolas, Audrey
    CANCERS, 2021, 13 (17)
  • [36] CO-EXISTENCE OF CYCLIN D1 AND VEGF EXPRESSION IS A POOR PROGNOSTIC FACTOR FOR UICC STAGE I-III COLORECTAL CANCER PATIENTS
    Wang, J. Y.
    Tsai, H. L.
    ANNALS OF ONCOLOGY, 2013, 24 : 27 - 27
  • [37] PD-L1 expression correlates with epithelial-to-mesenchymal transition (EMT) and exhibits improved prognostic outcomes in microsatellite stable colorectal cancer (MSS-CRC)
    Palomar De Lucas, B.
    Tarazona, N.
    Gimeno-Valiente, F.
    Gonzalez-Munoz, J. F.
    Huerta, M.
    Moro, D.
    Cervantes, A.
    Martinez-Ciarpaglini, C.
    VIRCHOWS ARCHIV, 2024, 485 : S158 - S159
  • [38] Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer
    Dunne, Philip D.
    O'Reilly, Paul G.
    Coleman, Helen G.
    Gray, Ronan T.
    Longley, Daniel B.
    Johnston, Patrick G.
    Salto-Tellez, Manuel
    Lawler, Mark
    McArt, Darragh G.
    ONCOTARGET, 2016, 7 (24) : 36632 - 36644
  • [39] Co-existence of cyclin D1 and vascular endothelial growth factor protein expression is a poor prognostic factor for UICC stage I-III colorectal cancer patients after curative resection
    Tsai, Hsiang-Lin
    Yeh, Yung-Sung
    Chang, Yu-Tang
    Yang, I-Ping
    Lin, Chih-Hung
    Kuo, Chao-Hung
    Juo, Suh-Hang
    Wang, Jaw-Yuan
    JOURNAL OF SURGICAL ONCOLOGY, 2013, 107 (02) : 148 - 154
  • [40] Prognostic impact of allelic losses in 1p32-36 (HYTM1), 4p15.2 (D4S2397), 5q22.2 (D5S346), 8p22 (D8S254), 18q12.3 (D18S474), and microsatellite instability for colorectal cancer
    Melcher, R.
    Kudlich, T.
    Luehrs, H.
    Katzenberger, T.
    Illert, B.
    Al-Taie, O.
    Einsele, H.
    Scheppach, W.
    Scheurlen, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)